CML-CP: Imatinib discontinuation feasible in children with sustained DMR for at least 2 yearsSeptember 26, 2021CML
CML-CP: BCR-ABL1 transcript doubling time predicts TFR failure after imatinib discontinuation September 26, 2021CML
Asciminib demonstrates superior efficacy than bosutinib in TKI-refractory CML-CP September 26, 2021CML
CML-CP: ELTS vs. Sokal score allows better prediction of response in patients receiving TKISeptember 26, 2021CML
CML-CP: Addition of PegIFN- to dasatinib well tolerated and effective in long term treatmentSeptember 26, 2021CML
Benefit-risk ratio favors 45 mg ponatinib as a starting dose in resistant CML-CPSeptember 26, 2021CML
Risk for vascular adverse events higher with nilotinib vs. imatinib in patients with CMLSeptember 26, 2021CML
Advanced phase CML: Factors influencing long-term survival after hematopoietic stem cell transplantationAugust 29, 2021CML
Thyroid abnormalities associated with better treatment response in CML-CP patients on TKI therapyAugust 29, 2021CML
